TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 05/26/24

2024-05-26 02:45:00 ET Summary Jiangsu Hengrui Medicine out-licenses global rights for its GLP-1 candidates to US startup Hercules in a deal worth up to $6 billion. Shanghai Degron Therapeutics partners with Takeda to identify multiple targets in oncology, neuroscience, and inflam...

2024-05-24 09:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-23 16:16:31 ET More on ADHD drugs New ADHD drugs could pay off for pharmaceutical companies Drug shortages in U.S. at highest level on record since 2001 Adderall shortage prompts FDA, DEA to ask for production boost Read the full article...

2024-05-20 01:30:00 ET Summary Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments. Zai Lab reported China’s NMPA approved Augtyro ...

Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection Canada NewsWire The Letter of Intent is an important ste...

2024-05-15 12:22:59 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation Takeda Pharmaceutical: Eohilia's FDA Approv...

2024-05-14 09:41:52 ET More on Scilex, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation Takeda Pharmaceutical: Eohili...

Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. Takeda’s presentations will spa...

2024-05-13 09:52:52 ET More on AC Immune Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune Financial information for AC Immune Read the full article on Seeking Alpha For further details see: AC Immune rockets ...

− Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression − AC Immune to receive upfront payment of $100 million upon closing and be eligible...